Department of Urology, Glickman Urologic and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Department of Urology, Glickman Urologic and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Urology. 2021 Jul;153:129-131. doi: 10.1016/j.urology.2020.11.076. Epub 2021 Feb 6.
The Breast Cancer Gene (BRCA) confers an 8.6-fold higher risk of developing prostate cancer in men ≤ 65 years of age and portends a worse prognosis as compared to noncarriers even in patients with low volume, localized disease. The BRCA2 gene, in particular, imparts a more biologically aggressive form of prostate cancer and a higher prostate cancer specific mortality. From a treatment standpoint, this translates to worse overall clinical outcomes for such patients. The most appropriate screening and management strategy for germline BRCA mutation carriers with prostate cancer is not known. Herein, we present an incidentally discovered prostate cancer in a 61-year-old BRCA1 and BRCA2 germline mutation carrier who was screened and managed using an individualized treatment approach.
乳腺癌基因 (BRCA) 使男性≤65 岁的前列腺癌发病风险增加 8.6 倍，与非携带者相比，即使在体积小、局部疾病的患者中，预后也更差。BRCA2 基因尤其赋予了更具生物侵袭性的前列腺癌形式和更高的前列腺癌特异性死亡率。从治疗的角度来看，这意味着此类患者的总体临床结局更差。对于携带胚系 BRCA 突变的前列腺癌患者，最适当的筛查和管理策略尚不清楚。在此，我们介绍了一名 61 岁 BRCA1 和 BRCA2 胚系突变携带者偶然发现的前列腺癌病例，该患者采用个体化治疗方法进行了筛查和管理。
